Azadyne
2 known investors
Azadyne is a UK biotech company and spin-out from Trinity College Dublin developing therapeutics based on tRNA modification and epigenetic regulation of cellular protein synthesis. Its work targets the treatment of disease through this novel mechanism.
Founders & leadership
VK
Vincent Kelly
SC
Stephen Connon
JM
J Michael Southern
Board
JR
Jason Rutt
Investors · 2
Competitors · 1
by search overlap
Companies competing with Azadyne for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- AZADYNE LTD
- Company number
- 11740078
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 24 Dec 2018
- Registered office
- 101 New Cavendish Street, 1st Floor South, London, W1W 6XH
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- FREYAGEN LIMITED (2018–2019)
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 23 Dec 2025 · next due 6 Jan 2027
Current officers · 4
- Stephen Joseph Connon — director, appointed 21 Feb 2019
- Jason Edward Rutt — director, appointed 24 Dec 2018
- Jonathan Stuart Synett — director, appointed 13 May 2019
- Paul Michael Tselentis — director, appointed 10 Nov 2022
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Azadyne do?
- Azadyne is a UK biotech company and spin-out from Trinity College Dublin developing therapeutics based on tRNA modification and epigenetic regulation of cellular protein synthesis. Its work targets the treatment of disease through this novel mechanism.
- Who founded Azadyne?
- Azadyne was founded by Vincent Kelly, Stephen Connon.
- Who are Azadyne's investors?
- Azadyne's investors include 24 Haymarket, NCL Technology Ventures Ltd..